RNAi, as a novel therapeutic modality, has an enormous potential to bring the era of personalized medicine one step further from notion into reality. However, delivery of RNAi effector molecules into their target tissues and cells remain extremely challenging. Major attempts have been made in recent years to develop sophisticated nanocarriers that could overcome these hurdles. This review will present the recent progress with the challenges and opportunities in this emerging field, focusing mostly on the in vivo applications with special emphasis on the strategies for RNAi delivery into immune cells.
Introduction
RNA interference (RNAi) is a natural cellular mechanism for RNA-guided regulation of gene expression. This regulation is carried out by double stranded ribonucleic acid (dsRNA) that suppresses the expression of specific genes with complementary nucleotide sequences, either by degrading specific messenger RNA (mRNA) or by blocking mRNA translation. RNAi can be activated exogenously by expressing short hairpin RNA (shRNA) and microRNA (miRNA) duplexes with viral vectors, or by incorporating synthetic small interfering RNAs (siRNAs), double stranded miRNA mimetics molecules, and anti-miRNA oligonucleotides (antagomirs) directly into the cell cytoplasm [1] [2] [3] . The viral vector tools offer advantages such as long sustained gene silencing, and ease expression of multiple copies of RNAi molecules from one transcript. However, due to safety concerns and interference to the endogenous mechanism of miRNAs, we choose not to discuss them in this review.
siRNA is a chemically synthesized double stranded RNA (dsRNA) of 19-23 base pairs with 2-nucleotides unpaired in the 5 -phosphorylated ends and unphosphorylated 3 -ends [4, 5] . Inside the cell cytoplasm, siRNAs are incorporated 1 Author to whom any correspondence should be addressed.
into RNA induced silencing complex (RISC), a protein-RNA complex that separates the strands of the RNA duplex and discards the passenger (sense) strand. The guide (anti-sense) strand then guides RISC to anneal and cleave the target mRNA or block its translation [2] (see figure 1) . By recycling the target mRNA, the RISC complex that incorporates the guide strand, may show a silencing effect for up to seven days in dividing cells and for several weeks in non-dividing cells. Furthermore, repeated administration of siRNA can result in stable silencing of its target [6] .
miRNAs are endogenous non-coding RNAs involved in post-transcriptional gene expression regulation. They are primarily transcribed as pri-miRNAs, long hairpin structured transcripts, and processed by RNAse III Drosha into 70-100 nucleotide pre-miRNAs, which are exported by Exportin 5 to the cytoplasm. There, RNAse III Dicer generates dsRNA of approximately 22 nucleotides, the mature miRNA. From this step, the mechanism is similar to that described above for siRNAs-the anti-sense strand of the mature miRNA is incorporated to microRNA containing RNA induced silencing complex (miRISC), whereas the other strand is degraded. The miRISC usually hybridizes to partially complementary binding sites on the 3 untranslated region of the target mRNAs, and silences their expression by interfering with translation or by initiating their degradation. The partial complementary Figure 1 . A schematic representation of the RNAi mechanism. The endogenous pathway of RNAi begins in the nucleus, where the pri-miRNA molecule is processed by RNAse III enzyme named Drosha and becomes pre-miRNA. Exportin 5 exports the pre-miRNA into the cytoplasm where it is processed by RNAse III Dicer and become the mature miRNA. From this point, the endogenous pathway is very similar to the exogenous pathway, in which synthetic RNAi molecules (siRNAs, miRNA mimetics and antagomirs) are inserted into the cell cytoplasm. The 19-23 double stranded RNA molecule is then incorporated into RISC (or miRISC), were the passenger strand is released and the guide strand mediates its target mRNA degradation or translation inhibition.
enables each individual miRNA to regulate many different mRNA targets (in fact, a single miRNA is predicted to target between 100 and 200 mRNAs [7] , and one specific mRNA to be regulated by different miRNAs [3, 8] ). RNAi could be exploited for miRNAs therapeutics by offering different tactics, both for silencing miRNA expression, for example with antagomirs, and for miRNA replacement, for example with double stranded miRNA mimetics (siRNA structure analogous molecules that are equivalent to the endogenous mature miRNA Dicer product). These strategies usually result in an increase or decrease of the miRNA's regulated proteins' expression levels, respectively [9, 10] .
Knocking down every gene of interest with siRNA, clusters of co-regulated genes with miRNA mimetics or endogenous miRNAs with antagomirs make the addressing of otherwise 'undruggable' targets (i.e. molecules without ligand binding domains or those that have a structural homology with other important molecules in the cell) possible. The elimination of clinical safety concerns associated with viral vectors and the reduced likelihood for interference to the endogenous microRNA machinery (which could happen due to saturation of enzymes or transport proteins), make RNAi molecules a promising new platform for therapy in personalized medicine [11] .
Despite this promise, utilizing RNAi for therapeutics is not a trivial task. For example, due to the large molecular weight (∼13 kDa), the net negative charge and their hydrophilicity, the efficiency with which naked molecules of siRNA cross the plasma membrane and enter the cell cytoplasm is very low [2, 12] . When injected intravenously, in addition to rapid renal clearance and susceptibility to degradation by RNAses, unmodified naked siRNAs are recognized by Tolllike receptors (TLRs). This often stimulates the immune system, hence provoking an interferon response as well as complement activation, cytokine induction, and coagulation cascades. Beside the undesired immune activation, those effects can suppress gene expression globally, generating offtarget and misinterpreted outcomes [12, 13] . Most of these obstacles are relevant for other naked RNA molecules such as miRNA mimetics and antagomirs. Therefore, there is a clear need for appropriate delivery systems for RNAi, all of which have to utilize cellular mechanisms for internalization, cargo release (from the carriers and escape from the endosomes), cargo accumulation in the cell cytoplasm and RISC activation. This review will present the recent progress in this emerging field, focusing on the in vivo applications for RNAi delivery, with special emphasize on the strategies for RNAi delivery to leukocytes, which are intrinsically hard to transfect and difficult to target. Most of the strategies discussed here have been developed for siRNA delivery. However, the recent accumulated knowledge regarding miRNA mechanisms and functions, along with the consolidated understanding of the huge therapeutic potential of this emerging field, make it reasonable to assume that in the near future those strategies as well as new ones will be adapted for antagomirs or miRNA mimetics delivery.
Cellular delivery strategies for RNAi
Most of the methods commonly used for in vitro or ex vivo delivery of RNAi are conventional transfection methods. Studies with purely physical methods such as microinjection and electroporation [14] [15] [16] [17] [18] [19] , as well as studies that used calcium co-precipitation [20] , commercial cationic polymers and lipids [4, [21] [22] [23] [24] [25] [26] [27] and cell penetrating peptides [28] [29] [30] [31] [32] , have demonstrated effective knockdown of desired genes. Except for the physical methods (in which the cell is subjected to an injection of small volumes of RNAi molecules directly into the cell cytoplasm or to a burst of electricity that causes pores in the membrane, hence elevating the ability of extracellular material to enter into cell), all the methods share a main characterization-a positive (cationic) charge that enables the complexing of the RNAi molecules and the interaction with the negatively charged plasma membrane.
Translation of RNAi into clinical practice
Silencing of gene expression in vitro is a great tool for functional and validation studies. Nevertheless, understanding gene expression in a disease model by validating a specific genes' role in vivo, along with the potential to induce therapeutic gene silencing, open new avenues for utilizing RNAi as a novel therapeutic modality and brings the era of theranostics (personalized medicine) a step further from a vision to a potential reality.
Despite the large diversity of available methods for in vitro and ex vivo RNAi delivery mentioned above, there are additional hurdles to overcome in translating these methods into clinical practice. As we detail below, the biggest hurdle facing the translation of RNAi therapeutics into the clinic is their delivery.
In vivo delivery of RNAi molecules
Local delivery of RNAi molecules has been demonstrated in various animal models [31, [33] [34] [35] [36] [37] and is employed in several ongoing clinical trials [38] . Based on local injections of naked or cationic lipid/polymer-formulated RNAi molecules, this method of treatment has demonstrated very promising outcomes. Nevertheless, regarding human therapeutics, this kind of delivery is relevant only for mucosal diseases and subcutaneous or other accessible tissues.
Systemic delivery of RNAi molecules is the most challenging task in this field. While cellular and local delivery strategies have to deal with the need for internalization, release, and accumulation of the RNAi molecules in the cell cytoplasm, delivery strategies for systemic treatment of an entire animal additionally enforces one to deal with the RNAi molecules' interactions with blood components, uptake by the reticuloendothelial cells and immune stimulation, degradation by RNAses, renal clearance, anatomical barriers (such as the liver which tends to accumulate foreign bodies), and penetration into the target tissue [39] .
Systemic delivery of naked RNAi molecules may occur by the hydrodynamic method. This method, whose precise mechanism is unsolved yet, involves rapid injection of a large volume of RNAi molecules in physiologic solutions (about 10% of the body weight administered within 5-10 s) [40, 41] . Hepatocytes cells in the liver are the main target of this approach. Different studies for siRNA delivery were done with this method, demonstrating functional knockdown of specific genes in animal liver [40] [41] [42] [43] . Nevertheless, due to volume overload side effects (such as right-sided heart failure), the hydrodynamic method is not relevant for human therapeutic use.
Naked siRNAs have been successfully utilized for targeting the kidney. When systematically administrated, large amounts of naked siRNA are excreted by the glomerulus (which excretes any molecule with molecular weight less than 40 kDa) and reabsorbed in the proximal tubule. The accumulation of free siRNA in the kidney is 40 times higher than in any other organ, an ideal property for selective gene therapy.
Studies in rat models for renal injury indicated functional silencing of p53, a major proapoptotic gene, and renal protection, both in single and multiple injection administration [44] .
QPI-1002, a drug from Quark Pharmaceuticals, is based on these studies, and being evaluated in phase I clinical trials for systemic delivery of p53-siRNA in acute renal injury and delayed graft function [39] .
Another strategy for using naked siRNAs systematically is their stabilization with locked nucleic acids (LNAs), synthetic RNA-like high affinity nucleotide analogs. Although a complete modification of siRNA with LNAs is impossible due to significant structural changes, siRNAs incorporated with a few LNAs did not lose their silencing ability [45] . LNA-modified siRNAs targeting a xenograft cancer model have shown to be much more stable in the serum and effective in inducing silencing of GFP expression [46] . In addition, those LNA-modified siRNAs reduced off-target gene regulation compared with unmodified siRNA. Another study [47] demonstrated that intravenously administrated LNA-modified siRNAs efficaciously reduced EGFP expression in the mouse lung bronchoepithelium.
Although more stable in serum, and resistant to nucleases than unmodified siRNAs, the LNA-modified siRNAs are still subject to renal clearance. Therefore, utilizing naked siRNAs systematically is less applicable when the target organ is not the kidney. Hence, strategies for systemic delivery of siRNA (and other RNAi molecules) must relay on nanocarriers.
Typically, the formal definition of nanotechnology requires that the nano-device or its essential components be man-made and between 1 and 100 nm at least in one dimension [48] . However, from a biological standpoint, the dimensions limitations of nanotechnology devices could be more flexible according to the operational and unique needs of biological systems and the breakthrough potential for patient care [48] [49] [50] [51] . Most of the carriers described in this review are within the formal dimensions of nano-devices, hence considered as nanocarriers. The other particles, whose diameter exceeds the strict 100 nm limitation, are still in close proximity and possess great clinical potential (see table 1 for carrier dimensions).
The engineering concepts and design of nanocarriers for RNAi delivery are summarized in box 1. Those general rules intend to solve or weaken the hurdles that nanocarriers face when systemically administrated into an organism (rodent, non-human primate or human). For example, in order to avoid undesired and probably toxic accumulation of the delivery system components in the body, the nanocarriers should be made from fully degradable materials and should act on specific cells or tissues while avoiding damaging others [51] .
To date, most of the developed strategies for RNAi delivery have been oriented and tested with siRNAs and not with miRNA mimics or antagomirs, probably as a consequence of the later discovery of the miRNA mechanism and its function (and hence the later understanding of their exquisite therapeutic potential) in comparison with siRNA. Consequently, most of the knowledge shared in this review focuses on the development of siRNA nanocarriers. However, we believe that most (if not all) of the strategies outlined here could easily be modified to serve as miRNA mimics or antagomir delivery vehicles.
The systemic siRNA delivery strategies are divided into two major categories: passive and active (targeted) Box 1. Engineering concepts and design of nanocarriers for RNAi delivery.
General requirements from nanocarriers for systemic administration:
• The nanocarrier should be made from well characterized, easily functionalized and biocompatible materials.
• It should have an extended circulating half-life and ability to evade the RES system. • It should avoid the induction of immune responses by evading the immune system.
• It should have a low rate of aggregation in order to avoid toxic accumulation in the body.
• It should be small enough to penetrate its target tissues but not too small to avoid renal clearance.
• It should accumulate in the target cells over other cells (or tissues).
• For higher effectiveness the nanocarrier should be either soluble or colloidal under aqueous conditions. • It should have a long shelf life.
Additional requirements from carriers for systemic RNAi delivery:
• To internalize into the target cell in a specific and selective manner.
• To ensure efficient release of RNAi molecules in target cell cytoplasm while escaping from the endosome.
• To ensure minimal recognition by RNA sensors inside the cell (such as TLR3, RIG-I and MDA5).
delivery. Passive delivery exploits the inherited tendency of nanoparticles to accumulate in cancerous or highly inflamed tissues due to the enhanced permeability and retention (EPR) effect or in organs of the reticuloendothelial system (RES), also known as the mononuclear phagocytic system. The EPR effect is the increased permeability of the blood vessels in tumors and highly inflamed tissues caused by rapid and defective angiogenesis, and the dysfunctional lymphatic drainage that retains the accumulated nanoparticles [52] . Different studies have shown that the efficacy of extravasation into tumors is higher with particles whose diameters are smaller then 200 nm [51, [53] [54] [55] [56] . The RES is part of the immune system, consisting of phagocytic cells located in reticular connective tissue, primarily monocytes and macrophages. These cells accumulate in lymph nodes, the spleen and the liver, and take up foreign particles believed to be intruders in the body, such as viruses, bacteria and parasites of different types, sizes, shapes and charges [57, 58] . Hence, it is not surprising that major attempts have been made to develop siRNA delivery systems for treating different liver diseases. Active (targeted) delivery is based on specific antibodies, ligands or ligand mimetics that direct the nanocarriers to specific target cells and tissues in order to achieve maximal therapeutic benefit, decrease the amount of drug required, and avoid nonspecific silencing and toxicity in bystander cells [51] . 
Passive systemic RNAi delivery
Stable nucleic acid-lipid particle (SNALP) is a ∼100 nm non-targeted liposome with low cationic lipid content that encapsulates siRNAs and is coated with a diffusible polyethylene glycol-lipid (PEG-lipid) conjugate [59, 60] . The PEG-lipid coat stabilizes the particle during formation and provides a neutral and hydrophilic exterior that prevents rapid systemic clearance. The lipid bilayer contains a mixture of cationic and fusogenic lipids, and enables the internalization of the SNALP and its endosomal escape while releasing the siRNAs payload. Biodistribution study indicates that most (28%) of the siRNAs carried by the SNALPs were accumulated in the liver (and only 0.3% in the lungs). Functional study of SNALP encapsulated ApoB-siRNA has shown significant reduction in ApoB mRNA levels and as a result a reduction in the levels of protein expression, serum cholesterol and lowdensity lipoprotein (the therapeutic benefit) [59] . Despite the presence of cationic lipids known to trigger toxicities [61, 62] , mice and non-human primates revealed no adverse effects except for liver enzyme release. Based on these results, a clinical trial is now being conducted to test the ability of SNALPs to deliver siRNAs for liver cancer treatment as well as for reduction of serum cholesterol levels. SNALP encapsulating siRNA against the polymerase gene of the Zaire strain has been shown to protect guinea pigs from the lethal challenge of the Ebola virus [63] . In a recent study [64] , the researchers tried to determine the best lipid formulation, regarding efficacy and safety, for siRNA delivery by SNALPs. They found that the SNALP formulation of the lipid DLin-KC2-DMA was well tolerated in both rodent and non-human primates and exhibited in vivo activity at siRNA doses as low as 0.01 mg kg −1 in rodents, as well as 0.3 mg kg −1 in nonhuman primates (in comparison with at least 1 mg kg −1 for the siRNAs that were used in previous SNALPs systems). Other formulations of cationic liposomes, with larger cationic lipid content than the SNALPs, have induced effective gene silencing, but they also show cytokine induction and toxicity and thus cannot be used for clinical evaluation.
Considering the significant toxicities that have been associated with cationic liposomes, neutral charge liposomes are very promising carriers for systemic delivery of siRNAs. 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nonpegylated liposomes encapsulating siRNA against different molecules expressed on melanoma and ovarian cancers inhibited tumor growth in human xenograft models [65, 66] . The accumulation of these liposomes in the cancerous tissues is based on the EPR effect.
Bio-inspired materials for RNAi delivery are the cationic lipidoid (synthetic lipid-like molecules) that is formulated with natural lipids to form liposomes for siRNA delivery. Lipidoid containing liposomes have been shown to deliver siRNAs that induce effective gene silencing (80% reduction in two different genes: ApoB and Factor VII mice's mRNA levels) in the liver. A single intravenous injection of cationic lipidoid containing liposome encapsulated ApoB-siRNA resulted in a 50% decrease in the protein level three days and up to two weeks after the treatment. Although no immune response was indicated, increases in the serum levels of two liver enzymes suggested liver toxicity [67] . Using combinatorial synthesis and screening of a different class of materials Love et al [68] identified a particular lipidoid formulation that enables gene silencing with very low doses of siRNAs (less than 0.01 mg kg −1 and 0.03 mg kg −1 in the liver of mice or nonhuman primates, respectively), and without observed adverse side effects. This formulation has demonstrated simultaneous silencing of five specific genes after a single intravenous injection [68] .
HK peptides are an additional effective delivery strategy for siRNAs. This system is based on the addition of histidines into poly-lysine peptides. While lysine is important for binding the siRNAs, histidines stabilize the particles and have an important role in buffering acidic endosomes, thereby leading to endosomal disruption and payload release. Specific ratios and patterns of histidine and lysine have been found to augment the siRNA delivery while carriers with a higher ratio of histidine to lysine content seemed to be more effective [69] . HK peptides carrying Raf-1-siRNA or human rhomboid family-1-siRNAs induced significant silencing of target genes and growth inhibition of tumor xenografts [70, 71] .
Atelocollagen is a biomaterial consisting of a lowimmunogenic fraction of pepsin-digested type I collagen from calf dermis. This biomaterial exhibits a stick-like structure, 1.5 nm in diameter, 300 nm in length, and 300 kDa in molecular weight [72] , similar in dimensions to carbon nanotubes but made from naturally occurring protein (collagen). Rich in positively charged residues (lysine and hydroxylysine), it complexes the negatively charged siRNAs and interacts with the plasma membrane, thus helping to incorporate the siRNAs into the cells. Although these particles have not been modified to target tumors, passive targeting due to the EPR effect causes the selective accumulation within the cancerous tissues, as shown in several studies with different tumor xenografts (i.e. [30, [73] [74] [75] ). Initial studies indicated that atelocollagen particles can be administered safely without induction of cytokines or observed toxicity to the tissues. Another study demonstrated that atelocollagenmiR-16 complexes injected into mouse tail veins efficiently delivered miR-16 to tumor cells on bone tissues in a xenograft model of prostate cancer. Functionally, those complexes significantly inhibited the growth of prostate tumors [76] .
Active (targeted) systemic RNAi delivery
siRNAs conjugated to other molecules is a common strategy for active delivery. Cholesterol-siRNA conjugate is one example. The specificity of this delivery system is determined by the lipoprotein to which the cholesterol-siRNAs conjugates are attached in the circulation. When the conjugates bind LDL, the particles are mainly taken up by the liver due to its LDL receptor expression, whereas when they bind HDL, they accumulate in the liver, the gut, the kidney and steroidogenic organs, all of which express scavenger receptor class B, type I (SR-BI) receptors, which bind HDL [77] . Cholesterol-ApoB-siRNA conjugate, as well as α-tocopherol [78] and lithocholic acid or lauric acid conjugated to ApoB-siRNA [79] , reduced serum cholesterol and ApoB mRNA levels in the liver. The same strategy was also employed for antagomir delivery to the mouse liver. Specific miR-122 silencing in mouse liver was demonstrated with 2 O-methylated antagomirs against miR-122 containing a cholesterol moiety in their 5 end. The silencing was long lasting and continued even 23 days post-antagomir injection. This miRNA silencing results in upregulation of several genes involved in cholesterol biosynthesis and downregulation of serum cholesterol levels [80] . Another example for the strategy of conjugating siRNAs to other molecules is the dynamic polyconjugates [81] . This system includes membrane-active polymers whose activity is masked until reaching the acidic environment of the endosomes. Using N-acetylgalactosamine, which binds to the asialoglycoprotein receptor, this system target hepatocytes. Like the SNALPs, these particles, when carrying ApoB-siRNAs, decreased ApoB mRNA levels in the liver.
PEI nanoplexes carrying siRNAs have also induced functional silencing in subcutaneously transplanted tumors in nude mice. Those particles are composed of RGD (Arg-Gly-Asp) peptide coupled via PEG (required for longer half-life, and reduced immunogenicity) to polyethylenimine (PEI, a cationic polymer that in addition to its ability to condense nucleic acids, has a pH-buffering property that disrupts endosomes, thus enabling it to reach the cytoplasm). When complexed with siRNAs, due to electrostatic interactions between the cationic polymers and anionic siRNAs, some RGD-PEG-PEI molecules form a polyplex, with the positively charged RGD-PEG components exposed on its surface. The targeting ability of this particle is based on the overexpression of a v integrins, to which RGD peptides bind, in certain cancers and in tumor vasculature [82] .
Cyclodextrin containing polycation (CDP) particles have been also successfully used for siRNA delivery into mouse subcutaneous tumors [83] . CDP is a polymer with a cyclic oligomeric glucose backbone that when complexed with siRNA assembles into a colloidal 50-70 nm particle. To achieve targeting, transferin-coupled PEG is attached to the surface of the particles to exploit the upregulation of Tf receptors in cancers. However, despite being considerably less toxic than conventional cationic polymers (such as PEI), safety experiments on non-human primates revealed that in the high concentration tested, injection of these particles induced elevation in blood urea (which might indicate kidney toxicity). In addition, a mild increase in serum liver enzyme levels and a mild increase in IL-6 levels (IL-6 is considered as a global marker for inflammation) were observed. Multiple injections of the particles induced antibodies to human-Tf. Despite those disadvantages, the efficacy of Tf-coupled CDP containing siRNAs for ovarian cancer and melanoma treatment is being evaluated now in a clinical trial with early positive results for gene silencing [84, 85] .
Antibody-protamine fusion protein carriers (3-15 nm in diameter) are unique systems for systemic siRNA delivery. These fusion proteins are made by molecular biology techniques (cloning of fragment of an antibody together with protamine (a basic protein) in a single transcript) and expressed in bacteria or mammalian cells. Protamines are relatively small (molecular weight of about 5-8 kDa) and highly basic proteins composed of 55-79% arginine residues [86] . These fusion proteins are build of a fragment of an antibody, which acts as a targeting agent, directing these carriers into a specific cell surface receptor, and the protamine is an siRNA binding protein, which neutralizes and condenses the siRNAs. ErbB2-protamine fusion protein in complex with siRNA significantly inhibited the growth of breast cancer cells [87] . A similar strategy was developed for targeting the brain, overcoming the obstacle of the blood-brain barrier. This strategy is based on a short peptide, derived from rabies virus glycoprotein (instead of antibody), with nonamer arginine residues at the carboxy terminus (RVG-9R), important for the glycoprotein-siRNA binding. The ability to target brain tissue by these particles is achieved due to RVG binding to specific receptors (acetylcholine receptors) on neurons. Intravenous injections of RVG-9R-anti-GFP-siRNAs into transgenic GFP mice resulted in a specific decrease in GFP expression in the brain. Furthermore, mice treated with intravenous RVG-9R-antiviral-siRNAs were protected against fatal viral encephalitis. Repeated treatments with those particles did not induce inflammatory cytokines or anti-peptide antibodies [88] .
Aptamer-siRNA chimeras are completely RNA based particles for specific delivery of siRNAs. This approach relies only on the fact that structured RNAs are capable of binding a variety of proteins with high affinity and specificity. The chimera includes both a targeting moiety, the aptamer, and an RNA-silencing moiety, the siRNA [89] . Modified aptamer-siRNA chimeras, in which the aptamer portion mediates binding to PSMA (a cell surface receptor overexpressed in prostate cancer cells and tumor vascular endothelium) with siRNA against Plk1 caused a pronounced regression of PSMA-expressing tumors in athymic mice after systemic administration [90] . This approach eliminates various side effects and is considered to have low immunogenicity. Additional advantages are the possibility to synthesize large quantities at a relatively low cost, and the smaller size of aptamers compared with that of antibodies (<15 kDa versus 150 kDa), which promotes better tissue penetration.
Different formulations of targeted cationic liposomes served for selective targeting of hepatic stellate cells (which are the major cell population involved in the formation of scar tissue in response to liver damage, named fibrosis) or solid tumors. Stellate cells express receptors for retinol, the binding protein which efficiently uptakes vitamin A. Based on these, injection of cationic liposomes coupled to vitamin A and complexed with siRNA to a murine key fibrogenesis factor (gp46) into cirrhotic mice, silenced the specific gene in mouse liver and resolved fibrosis [91] . 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) liposomes encapsulating HER2-siRNAs and containing histidine-lysine peptides (to enhance the escape from the endosomes) and a single-chain antibody fragment targeting transferrin receptors (elevated on the membranes of tumor cells) on their surface, have been targeted to a tumor xenograft and inhibited its growth [92] . Anisamide-PEG-liposomespolycation-DNA (anisamide-PEG-LPDs) are unilamellar cationic liposomes coated with PEG-linked anisamide (a small-molecule compound binding sigma receptors) on their surface, and a protamine-condensed mixture of siRNAs and a carrier calf thymus DNA in their core. Encapsulating EGFR-siRNA, anisamide-PEG-LPDs injected intravenously into tumor-bearing mice, have been shown to increase mouse sensitivity to chemotherapy [93] . Unfortunately, these particles induced a significant increase in serum cytokine levels, thus weakening the potential for clinical therapeutic use. However, it is important to note that cytokine response is not always deleterious to therapy and there are cases when immune activation could enhance the therapeutic effects.
Targeted delivery systems for leukocytes
Utilizing RNAi to manipulate gene expression in leukocytes holds great promise for the drug discovery field, as well as for facilitating the development of new therapeutic platforms for leukocyte-implicated diseases such as inflammation, blood cancers, and leukocyte-tropic viral infections. However, due to their resistance to conventional transfection methods and to their dispersing in the body, systemic delivery to leukocytes is even more challenging than the systemic delivery to other organs and tissues.
Kortylewski et al [94] used siRNAs synthetically linked to a CpG oligonucleotide agonist of TLR9 ( figure 2(A) ) for targeting myeloid cells and B cells (both are key components of the tumor microenvironment) that express this receptor. These particles simultaneously silenced stat3 by siRNA and activated TLR responses by their agonists. Consequently, they effectively shifted the tumor microenvironment from pro-oncogenic to anti-oncogenic (by causing activation of tumor associated immune cells and potent antitumor immune responses). This strategy is a good example of the case in which immune activation enhances the therapeutic effect.
Two studies from the same group presented newly developed siRNA delivery systems for treating viral infections ( figure 2(B) ). scFvCD7-Cys is a single-chain antibody against CD7 (a surface antigen present on the majority of human T lymphocytes) that was modified to include a cysteine (Cys) residue for conjugation to a 9 arginine (9R) peptide. This conjugate was used for targeted delivery of CCR5 (a chemokine receptor that function as co-receptor for HIV entry into T lymphocytes) and Vif/Tat (HIV replication proteins)-siRNAs payloads into T cells, and has been demonstrated to suppress HIV infection in humanized mice without inducing toxicity in their target cells [95] . A similar approach for treating dengue virus infected cells employed DC3 (12-mer peptide that targeting dendritic cells (cells that sample their environment))-9R for targeting, with TNF-α (which plays a major role in dengue pathogenesis) or specific highly conserved sequence in the viral envelope-siRNAs. These complexes significantly reduced virus induced production of TNF-α and succeeded in suppressing the viral replication in monocyte derived dendritic cells and macrophages in vitro. In vivo, treatment of mice with intravenous injection of DC3-9R-complexes carrying TNF-α-siRNAs effectively suppressed this cytokine production by dendritic cells [96] .
Zheng et al [97] have also developed a strategy for specific delivery of siRNAs into dendritic cells. Their strategy is based on immunoliposomes decorated with monoclonal antibody against DEC-205 ( figure 2(C) ), a dendritic cell specific protein.
Those particles containing anti-CD40 siRNAs, when injected intravenously to mice, demonstrated selective siRNA uptake in immune organs and functional silencing of CD40 that resulted in immune modulation.
Antibody-protamine fusion carriers have also been shown to be an efficient siRNA delivery system to leukocytes. In a fundamental study, Song et al [87] have designed a protamine-antibody fusion protein by fusing protamine to the C terminus of the heavy chain Fab fragment of an HIV-1 envelope antibody. These particles complexed siRNAs targeted against the HIV-1 capsid gene gag, inhibited HIV replication in hard to transfect, HIV infected primary T cells ex vivo. Based on this system, we have developed our approach [98] for targeting leukocytes, which is based on integrins, cell adhesion molecules that mediate cellcell and cell-matrix interactions [99] . We have developed single-chain variable fragment antibody (scFv)-protamine fusion proteins ( figure 2(D) ) utilizing the lymphocyte function associated antigen-1 (LFA-1) integrin, which is expressed in all leukocytes' subtypes, for selective targeting. The use of LFA-1 for targeting leukocytes is supported by its exclusive expression on leukocytes, its constitutive internalization and recycling activity and its ability to undergo activationdependent conformational changes. Using these antibodyprotamine fusion proteins we have demonstrated selective delivery of siRNAs into leukocytes both in vitro and in vivo. Importantly, neither lymphocyte activation nor interferon response was indicated [98] . Furthermore, by targeting these fusion proteins to the high affinity conformation of LFA-1 that characterizes activated lymphocytes, we demonstrated even more selective gene silencing, which unlike most immunosuppressive therapies, could provide a way to overcome the unwanted immune stimulation without global immunosuppressive effects on bystander immune cells. Additionally, due to the prevalenve of aberrant affinity modulation of integrins in a variety of leukocyte-implication diseases [100, 101] , targeting the high affinity conformation of LFA-1 seems to be very promising therapeutic strategy [98] .
Next, in order to increase payload and achieve more robust targeted gene silencing, we have generated integrintargeted and stabilized nanoparticles (I-tsNP, figures 2(E) and 3). I-tsNPs were engineered by the guidelines outlined in box 1.
Namely, we have developed neutral lipid based nanoparticles, made from phospholipids and cholesterol that was extruded under polycarbonate filters to form a uniform ∼80 nm (after extrusion and before adding targeting moieties) in diameter nanoparticles. The particles have been surface functionalized with a polysugar named hyaluronan Figure 3 . Schematic illustration of the process involved in generating I-tsNPs. A multilamellar vesicle (MLV) is made by the lipid film method and then extrusion is carried out under filters with defined sizes. The extrusion forms an ∼80 nm diameter unilamellar vesicle (ULV) from MLV. The cross-linker EDAC is then used to covalently bind the glycosaminoglycan hyaluronan and attached it to the ULV. A monoclonal antibody (mAb) to the integrin is covalently attached to hyaluronan-coated nanoparticles by EDAC/NHS reaction and generates the I-tsNPs that are purified with a size exclusion column. Rehydrating lyophilized I-tsNPs with water containing protamine-condensed siRNAs entrap the condensed siRNAs within the nanoparticle.
(HA), a naturally occurring glycosaminoglycan. The HA coating endow the carriers with long circulation (similar to polyethylene glycol-PEG), a scaffold for antibody binding and a built-in cryoprotection in a cycle of lyophilization and rehydration [102] [103] [104] [105] . The targeting ability of the particles has been achieved by attaching a monoclonal antibody against β 7 integrin (which is highly expressed in gut leukocytes) to the HA-coated nanoparticles [105] . Made from natural biomaterials, these nanoparticles (final diameter of ∼100 nm) offer a safe platform for siRNA delivery, avoiding cytokine induction and liver damage. Enabling the usage of low doses of siRNAs, this system, in addition to advantages such as high payload capacity (∼4000 siRNA molecules per particle) and low off-target effects and toxicities, is economically promising. To examine the targeting ability specifically to the gut, we labeled the nanoparticles with non-exchangeable 3 H-cholesterol and examine the biodistribution to different organs in the present of colitis. We found that the particles have preferential accumulation in the gut (both the colon and the small intestine) with reduce accumulation in the liver and spleen ( figure 4(A) ). We have recently shown, using positron emission tomography (PET) imaging, that the targeting agent on the particles' surface, the antibody against β 7 integrin (labeled with 64 Cu), selectively targets leukocytes that home to the gut and therefore could direct the antibody-decorated particles into sites of gut inflammation such as colitis [106] . Utilizing the I-tsNP system, we identified cyclin D1 (CD1), a regulator protein of the entry into, and the progression throughout the cell cycle, as a potential novel target for inflammatory bowel diseases (such as Ulcerative Colitis and Crohn's disease). Mice that were intravenously injected with siRNAs against CD1 every two days could suppress intestinal inflammation whilst maintaining their weight compare to control groups that dramatically decreased in bodyweight ( figure 4(B) ). Interestingly, β 7 I-tsNPs with CD1-siRNA shifts the inflammatory response from a pro-inflammatory to more of an anti-inflammatory response, by decreasing the levels of the pro-inflammatory cytokines TNF-α and IL-12p40 compared to all controls (figure 4(C)), hence revealing that CD1 operates as a master regulator of the pro-inflammatory cytokines.
Since I-tsNP is a platform, by changing the surface directing agent and the payload inside the particles, it is possible to target other cell types and deliver different siRNAs that will silence specific genes. I-tsNPs surface modified with an LFA-1 integrin-targeted antibody, were used for delivery of CCR5-siRNAs to human lymphocytes and monocytes. This system has been shown to protect mice from HIV infection [107] . LFA-1 I-tsNPs with CCR5-siRNAs did not induce interferon response or TNF-α (inflammatory cytokine) secretion, hence strengthening their potential for clinical relevance.
Summary
In this topical review, we described a variety of delivery systems made using different types of material and provided a rationale and some engineering concepts for designing new nanocarriers for RNAi delivery. Although there is no clinical approved RNAi delivery system yet, we are convinced that in the coming years this situation will change drastically. We base this assumption on one of the major advantages of RNAi delivery systems-the relative ease of altering them for purposes other than the original purpose. Changing the targeting agent in active delivery systems (by replacing the antibody or the ligand decorating the nanoparticle surface) or the payloads inside the nanoparticle (by using different sequences for targeting different genes, or by changing the RNAi molecules, for example from siRNA to miRNA mimetics), both in active and passive delivery systems, opens new avenues for treating a diversity of diseases as well as adjusting the treatment to the unique molecular gene expression abnormalities of a specific patient in a personalized approach [11] . Still, since no 'magic bullet' is available, there is the need to look for novel, effective methods to deliver RNAi effector molecules to specific cell types. This will be an interdisciplinary effort bringing together material scientists, engineers, chemists, physicists and biologists to solve this fundamental problem.
Much data has been accumulated in recent years concerning the specific roles of miRNA in health and disease [10, 108, 109] . Nevertheless, this data still has not been incorporated into therapeutic tools. It is likely that in the near future the existing strategies for siRNA delivery will also be exploited for therapeutic delivery of miRNA mimetics and antagomirs. This emerging field, consistent with the miRNA natural function, holds enormous therapeutic promise, for treating immune system pathologies and others, affecting simultaneously many targets mRNAs, or multiple Figure 4 . Representing experimental results with β 7 I-tsNP. (A) β 7 I-tsNP is a specific RNAi delivery system into gut leukocytes as indicated by the biodistribution of radiolabeled β 7 I-tsNPs in mice with or without colitis. Biodistribution of the nanoparticles was measures 12 h after injection in a total of six mice per group in three independent experiments. SP-spleen, PLN-peripheral lymph node, PP-Peyer's patches (a lymphoid organ in the gut), MLN-mesenteric lymph node, SI-(small intestine), ND-not detectable. (B + C) delivery of CD1-siRNA by β 7 I-tsNP alleviated intestinal inflammation in induced colitis. Mice were treated with intravenous injections of CD1-or luciferase (Luci, a control sequence of gene that does not exist in mice)-siRNAs entrapped in either β 7 I-tsNPs or IgG-sNPs (nanoparticles covalently attach to non-binding mAb), or naked CD1-siRNA, at days 0, 2, 4, and 6 (three independent experiments with a total of six mice per group). (B) Changes in body weight (one of the common parameters for mouse health evaluation) due to the different treatments. (C) mRNA expression of CD1 and cytokines in the gut due to the different treatments. mRNA expression was measured by qRT-PCR with homogenized colon samples harvested at day 9 after the first injection.
* * indicate p < 0.01, * * * indicate P < 0.001.
gene networks, and hence enabling a more comprehensive regulation specifying the desired cell phenotype.
